Aptimmune Biologics, Inc. – Trademark Portfolio
Entity Type: 03
Aptimmune Biologics, Inc. holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 4 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 5 Nice Classification classes. Currently, 5 trademarks are registered. Notable registered marks include ZMAC, APTIMMUNE, and BARRICADE. The owner is based in St. Louis, MO.
Suite 305
1005 N. Warson Road
St. Louis, MO 63132
Showing of trademarks Trademarks
Trademark Classifications
Aptimmune Biologics, Inc.'s trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Aptimmune Biologics, Inc. have?
Aptimmune Biologics, Inc. has 7 U.S. trademarks filed with the USPTO. Of these, 5 registered, 2 abandoned.
What trademark classes does Aptimmune Biologics, Inc. file in?
Aptimmune Biologics, Inc. files trademarks across 5 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 40 (Treatment & Processing), Class 1 (Chemicals). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.
What are Aptimmune Biologics, Inc.'s most well-known trademarks?
Aptimmune Biologics, Inc.'s registered trademark portfolio includes well-known marks such as ZMAC, APTIMMUNE, and BARRICADE. These are among 5 currently registered trademarks in the portfolio.
What is Aptimmune Biologics, Inc.'s trademark registration success rate?
Aptimmune Biologics, Inc. has a 71% trademark registration rate, with 5 out of 7 resolved applications resulting in successful registration. Currently, 0 applications are pending review.